PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 16, 2019Journal of Nuclear Medicine13 citationsOpen Access

18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 1. Improved Risk Stratification for MRI-Guided Transrectal Prostate Biopsies

View Full Paper
MDMatthew S. DavenportFlorida State UniversityJMJeffrey S. MontgomeryNorfolk State UniversityLKLakshmi P. KunjuUniversity of Michigan

Key Points

Key points are not available for this paper at this time.

Abstract

A prospective single-arm clinical trial was conducted to determine whether 18 F-choline PET/mpMRI can improve the specificity of multiparametric MRI (mpMRI) of the prostate for Gleason 314 prostate cancer. Methods: Before targeted and systematic prostate biopsy, mpMRI and 18 F-choline PET/CT were performed on 56 evaluable subjects with 90 Likert score 3-5 mpMRI target lesions, using a 18 F-choline target-to-background ratio of greater than 1. 58 to indicate a positive 18 F-choline result. Prostate biopsies were performed after registration of real-time transrectal ultrasound with T2weighted MRI. A mixed-effects logistic regression was applied to measure the performance of mpMRI (based on prospective Likert and retrospective Prostate Imaging Reporting and Data System, version 2 PI-RADS, scores) compared with 18 F-choline PET/mpMRI to detect Gleason 314 cancer. Results: The per-lesion accuracy of systematic plus targeted biopsy for mpMRI alone was 67. 8% (area under receiver-operating-characteristic curve AUC, 0. 73) for Likert 4-5 and 70. 0% (AUC, 0. 76) for PI-RADS 3-5. Several PET/MRI models incorporating 18 F-choline with mpMRI data were investigated. The most promising model selected all high-risk disease on mpMRI (Likert 5 or PI-RADS 5) plus low-and intermediate-risk disease (Likert 4 or PI-RADS 3-4), with an elevated 18 F-choline targetto-background ratio greater than 1. 58 as positive for significant cancer. Using this approach, the accuracy on a per-lesion basis significantly improved to 88. 9% for Likert (AUC, 0. 90; P, 0. 001) and 91. 1% for PI-RADS (AUC, 0. 92; P, 0. 001). On a per-patient basis, the accuracy improved to 92. 9% for Likert (AUC, 0. 93; P, 0. 001) and to 91. 1% for PI-RADS (AUC, 0. 91; P 5 0. 009). Conclusion: 18 F-choline PET/ mpMRI improved the identification of Gleason 314 prostate cancer compared with mpMRI, with the principal effect being improved risk stratification of intermediate-risk mpMRI lesions.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Davenport et al. (2019) studied this question.

synapsesocial.com/papers/6a1f6be5d09bc027e483700ehttps://doi.org/10.2967/jnumed.119.225789
Ask AI
Helpful
Bookmark
Share
View Full Paper